Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleBCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.AuthorsHughes, T P; Saglio, G; Quintás-Cardama, A; Mauro, M J; Kim, D-W; Lipton, J H; Bradley-Garelik, M B; Ukropec, J; Hochhaus, ASubjectsGENETIC mutation; DASATINIB; IMATINIB; TREATMENT of chronic myeloid leukemia; NILOTINIB; DRUG resistancePublicationLeukemia (08876924), 2015, Vol 29, Issue 9, p1832ISSN0887-6924Publication typeJournal ArticleDOI10.1038/leu.2015.168